Being Patient speaks with C-Suite business and biotech leader Wendy Nelson, PhD, about her discovery that she carries two copies of Alzheimer’s genetic biomarker APOE4, a gene variant associated with heightened Alzheimer’s risk, and the way this revelation has changed the way she thinks about brain health.

Nelson is currently the chief business officer for a strategic advisory company in the life sciences space and has 25 years of business development, project management, operational, and R&D experience in biotechnology and large pharmaceutical companies, as well as in global CROs. She is also president and founder of the Boston Biotech Forum. She’s an inventor on multiple patents and patent applications and has authored a number of scientific publications.


We rely on donations to bring you the latest research on dementia and brain health and to support our amazing team of independent journalists. Please consider donating to support of our mission of giving people impacted by dementia a better resource and connection to experts at the forefront of research. Our audience has grown so rapidly; we have exciting plans for the future to enhance our coverage even further but we need your help. Please consider making a contribution to help fund Being Patient's editorial costs.
https://beingpatient.nationbuilder.com/

---------------------------------------------------------------------------------------------------------------
Don't miss out on our live talks:
www.beingpatient.com/events

Stay connected on social media:
To catch our Brain Talks live, join our Facebook page:
  / beingpatient.  .

To learn more about us, follow us on Instagram:
@beingpatientvoices

For the latest news on dementia research and lifestyle tips, visit our site:
https://www.beingpatient.com/